Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study

Abstract

Abstract Background Chronic liver disease (CLD) is often complicated by severe thrombocytopenia (platelet count 50,000/µL at baseline: the proportions of patients who did not require platelet transfusion were 84–96%, which might be overestimated. Methods The efficacy and safety of lusutrombopag were retrospectively investigated in CLD patients with platelet count of 50,000/µL. However, lusutrombopag is effective and safe for CLD patients with a platelet count of < 50,000/µL.

Keywords

• Liver cirrhosis
• Thrombocytopenia
• Thrombopoietin receptor agonist
• Platelet transfusion